U.S. Consumer Durables Stock News

NYSE:MUR
NYSE:MUROil and Gas

Is It Time To Reassess Murphy Oil (MUR) After Recent Share Price Weakness?

If you are wondering whether Murphy Oil's current share price really reflects its underlying value, you are not alone. This article is designed to help you weigh what the market is pricing in. Recently, the stock has been under pressure, with a 7 day return of an 8.6% decline, a 30 day return of a 3.7% decline and a year to date return of a 6.4% decline, while the 1 year return sits at 1.6% and the 3 year return at a 20.6% decline. These moves have come as investors continue to reassess...
NasdaqGS:EXTR
NasdaqGS:EXTRCommunications

Extreme Networks AI Partner First Program Puts Channel At Center For Growth

Extreme Networks (NasdaqGS:EXTR) has launched its new Partner First program, focused on reshaping how partners work with the company. The program introduces unified global frameworks, transparent deal registration, and AI powered sales assistance for channel partners. Partner First is designed to streamline engagement and support partner profitability across Extreme Networks' global ecosystem. Extreme Networks, a networking solutions provider, is putting partners at the center of its go to...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Is There Now An Opportunity In Open Text (OTEX) After Recent Share Price Weakness

If you are wondering whether Open Text is attractively priced today, the recent share moves and current valuation score give you a lot to work with. The stock closed at US$28.80, with a 13.0% decline over the last 7 days and a 13.7% decline over the last 30 days, while the 1 year return stands at 5.3% and the 5 year return at 29.3% decline. These price moves sit against a backdrop of ongoing attention on large software providers and their ability to keep delivering reliable cash flows and...
NYSE:BXP
NYSE:BXPOffice REITs

BXP Advances Portfolio Plan With Over US$1b Sales And Undervalued Shares

BXP has completed more than $1.0b of property sales, including residential, land, and non core office assets. The transactions occurred across several key gateway markets as part of a multi year portfolio optimization plan. These sales contribute to BXP's progress toward its $1.9b asset disposition target for 2025 to 2027. For investors watching NYSE:BXP, the latest $1.0b plus in completed property sales comes at a time when the stock trades around $65.63. Recent share performance has been...
NYSE:DHI
NYSE:DHIConsumer Durables

D.R. Horton (DHI) Margin Compression To 9.9% Tests Bullish Growth Narratives

D.R. Horton (DHI) opened fiscal Q1 2026 with revenue of US$6.9b and basic EPS of US$2.03, putting a fresh quarterly snapshot alongside a trailing twelve month EPS of US$11.07 on revenue of US$33.5b and net income of US$3.3b. Over the past year, the company has seen quarterly revenue range from US$7.6b to US$10.0b and basic EPS move between US$2.03 and US$3.95, giving investors a clear view of how the current print sits within recent trading conditions and setting the stage for a closer look...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

Is It Time To Revisit Blue Bird (BLBD) After Recent Share Price Pullback?

If you are wondering whether Blue Bird's current share price still offers value, the key question is how the market is weighing its recent performance against what the business could justify over time. The stock last closed at US$49.08, with returns of 0.3% over the past week, a 5.1% decline over 30 days, a 5.0% gain year to date and 16.7% over the last year, plus a very large return over three years and a 127.4% gain over five years. Recent headlines around Blue Bird have focused on the...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN) Is Down 12.6% After Positive Phase 2 OCU410 Data in Geographic Atrophy

Earlier in January 2026, Ocugen announced positive preliminary 12‑month Phase 2 ArMaDa data for OCU410 in geographic atrophy secondary to dry age‑related macular degeneration, showing reduced lesion growth and favorable safety across evaluated patients. An interesting highlight is that medium doses produced greater lesion growth reduction than high doses, and no serious OCU410‑related adverse events were reported in either Phase 1 or Phase 2 so far. Next, we’ll assess how this early OCU410...
NYSE:AVB
NYSE:AVBResidential REITs

AvalonBay Dividend Tax Clarity Highlights Valuation Appeal And Key Risks

AvalonBay Communities, NYSE:AVB, has released the final tax treatment classification for its 2025 dividend distributions. The update details how different portions of the 2025 dividends will be categorized for tax purposes under current regulations. The announcement gives existing and prospective shareholders clearer information for tax planning around AVB’s upcoming payouts. AvalonBay Communities, NYSE:AVB, is putting hard numbers around its 2025 dividend tax classifications at a time...
NYSE:FBIN
NYSE:FBINBuilding

Is Fortune Brands Innovations (FBIN) Offering Value After Its Recent 30 Day Share Price Rebound

If you are wondering whether Fortune Brands Innovations is offering value at its current share price, this article walks through what the numbers are really saying about the stock. The share price recently closed at US$58.98, with a 15.6% return over the last 30 days but a 19.2% decline over the past year, which can change how investors view both its potential and its risk. Recent news around the company has focused on its positioning within the capital goods sector and how investors are...
NasdaqGS:PZZA
NasdaqGS:PZZAHospitality

Will Earnings Miss and Protein-Crust Experiment Change Papa John’s (PZZA) Investment Narrative?

Papa John’s International recently reported a quarter with flat year-on-year revenue that fell short of analyst expectations, alongside a miss on full-year EBITDA guidance and revenue estimates. At the same time, the company is experimenting with wellness-oriented innovation through a one-day, protein-infused crust pizza trial for Papa Rewards members at a single Atlanta location. Next, we’ll explore how the earnings miss and cautious analyst sentiment may influence Papa John’s investment...
NYSE:BHVN
NYSE:BHVNBiotechs

Biohaven (BHVN) Is Up 15.6% After Showcasing MoDE and TRAP Degrader Data in Autoimmune Diseases

Earlier in January 2026, Biohaven reported encouraging early clinical experience from its proprietary MoDE™ and TRAP™ extracellular protein degrader platforms, showing rapid removal of disease-causing proteins and associated clinical improvements in IgA nephropathy and Graves’ disease, alongside continued progress in its broader neurology and rare disease pipeline. The company also used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to spotlight these first-in-class...
NYSE:MMM
NYSE:MMMIndustrials

3M (MMM) Margin Compression To 13% Challenges Bullish Earnings Narratives

3M (MMM) has wrapped up FY 2025 with fourth quarter revenue of US$6.1b and basic EPS of US$1.08, alongside trailing 12 month revenue of US$24.9b and EPS of US$6.05 that frame how the latest results sit in a broader earnings picture. The company has seen quarterly revenue move from US$6.0b in Q4 2024 to US$6.1b in Q4 2025, while basic EPS shifted from US$1.34 to US$1.08 over the same period, setting a mixed backdrop for any discussion of earnings quality and momentum. With trailing net profit...
NYSE:VOYG
NYSE:VOYGAerospace & Defense

Voyager Patent And NASA Deal Spark Questions On Undervalued Growth Potential

Voyager Technologies secured a patent for microgravity based optical crystal manufacturing, tied to planned testing on the International Space Station. The company also won a NASA contract focused on STEM workforce development for space operations. These developments connect Voyager’s space manufacturing ambitions with education and hardware programs backed by a major government agency. For investors watching NYSE:VOYG, these announcements come with the stock at a recent close of $32.87 and...
NYSE:NATL
NYSE:NATLDiversified Financial

NCR Atleos Epirus Bank ATMaaS Deal Tests Growth Versus Valuation Concerns

NCR Atleos (NYSE:NATL) has partnered with Epirus Bank in Greece to modernize the bank's ATM network. The agreement introduces a branded ATM as a Service model using the Atleos platform and Cashzone network. The partnership is intended to expand cash access and improve self-service banking for Epirus Bank customers across Greece. NCR Atleos focuses on self-service banking technology and ATM outsourcing, and this new agreement with Epirus Bank provides another data point on how its ATMaaS...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Ross Stores Balances Same Store Sales Strength With Aggressive Expansion

Ross Stores (NasdaqGS:ROST) is reporting strong same store sales growth, reflecting solid demand for its off price offering. The company has completed a CEO transition while maintaining operational momentum. Management is continuing with an aggressive store expansion program across its footprint. Ross Stores, trading at $189.69, has seen its shares rise 28.8% over the past year and 79.6% over the past five years. Over the past three years, the stock is up 66.5%, while year to date it is up...
NasdaqGS:TXRH
NasdaqGS:TXRHHospitality

Texas Roadhouse Margins Improve As Stable Traffic Supports Earnings Outlook

Texas Roadhouse (NasdaqGS:TXRH) is seeing improving gross margins, supported by stable customer traffic and favorable commodity dynamics. Recent cuts to tariffs on Brazilian beef are expected to ease input costs for the company. Consistent customer traffic and rising same-store sales continue to stand out against broader industry concerns about wage and commodity inflation. Texas Roadhouse, the casual dining steakhouse chain, sits at the center of several important shifts in the restaurant...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data

Monte Rosa Therapeutics (GLUE) just reported positive interim Phase 1 data for MRT-8102, with strong target engagement, reductions in hsCRP and IL-6, and a favorable safety profile that appears to have caught investors' attention. See our latest analysis for Monte Rosa Therapeutics. The positive MRT-8102 update lands after a very strong run in the shares, with a 30-day share price return of 57.27% and a 90-day share price return of 161.39%. The 1-year total shareholder return is extremely...
NasdaqGS:METC
NasdaqGS:METCMetals and Mining

Jefferies Upgrade Puts Ramaco’s Coal And Rare Earth Story In Focus

Jefferies has upgraded Ramaco Resources (NasdaqGS:METC) from Hold to Buy. The upgrade is linked to potential upside in metallurgical coal prices. Jefferies also points to positive sentiment around Ramaco's Brook Mine rare earth project. Geopolitical developments are a key part of the thesis behind the new rating. Ramaco Resources is a producer of metallurgical coal used primarily in steelmaking. Any shift in coal pricing can quickly change how investors view the stock. The new rating from...
NYSE:ENS
NYSE:ENSElectrical

EnerSys Rally Tests Gap Between Share Price Momentum And Fundamentals

EnerSys (NYSE:ENS) has seen a sharp rise in its share price over the past six months. The stock move comes alongside reports of declining unit sales over the last two years. Revenue growth forecasts are described as modest, with gross margins remaining low. Investors are weighing strong quarterly results against these underlying business challenges. EnerSys, a supplier of energy storage and related solutions, now sits in a spotlight that is as much about its operations as its stock chart...
NYSE:MGY
NYSE:MGYOil and Gas

BofA Upgrade Puts Magnolia Oil And Gas Execution In Focus

BofA Securities upgraded Magnolia Oil & Gas (NYSE:MGY) to Buy, citing strong operational performance. The call highlights resilience in a challenging commodity price environment and recent production results at key oil fields. Several institutions have issued positive commentary on Magnolia Oil & Gas, pointing to its balance sheet and development plans. Magnolia Oil & Gas focuses on oil and gas production, with core assets that have drawn fresh attention after recent field results. For you...
NasdaqGS:FAST
NasdaqGS:FASTTrade Distributors

Fastenal (FAST) Margin Stability At 15.3% Reinforces Premium Valuation Narratives

Fastenal (FAST) just wrapped up FY 2025 with fourth quarter revenue of US$2.0b and EPS of US$0.26, capping a trailing twelve month run that produced US$8.2b in revenue and EPS of US$1.10. Over the past year, the company has seen revenue move from US$7.5b to US$8.2b and EPS edge from about US$1.00 to US$1.10, while net income on a trailing basis has tracked around US$1.2b. With net profit margins holding in the mid-teens, investors now have a clearer view of how consistent profitability and...
NYSE:CMA
NYSE:CMABanks

Comerica (CMA) Premium P E Challenges Modest Earnings Growth Narrative After FY 2025 Results

Comerica (CMA) just wrapped up FY 2025 with fourth quarter revenue of US$836 million and basic EPS of US$1.28, supported by trailing twelve month revenue of US$3.27 billion and EPS of US$5.33. Over recent periods, the bank has seen revenue move from US$3.20 billion and EPS of US$5.05 in the twelve months to Q4 2024 to US$3.27 billion and EPS of US$5.33 in the latest twelve month stretch, giving investors a clearer read on how earnings and top line are tracking together. With a trailing net...
NYSE:BKSY
NYSE:BKSYProfessional Services

A Look At BlackSky Technology (BKSY) Valuation As Gen 3 Renewal Contracts Signal Growing Customer Demand

BlackSky Technology (BKSY) has signed multiple Gen 3 expansion contracts as early access pilot programs move into renewal deals, highlighting continuing customer uptake for its AI-enabled, space-based intelligence services across several regions. See our latest analysis for BlackSky Technology. The new Gen 3 renewal contracts arrive at a time when momentum in BlackSky Technology’s shares has been building, with a 30 day share price return of 42.18% and a year to date share price return of...
NasdaqGS:CLMT
NasdaqGS:CLMTOil and Gas

Should Calumet’s $405 Million High-Coupon Refi Shift Reshape the CLMT Debt Story?

Earlier this month, Calumet, Inc. announced that Calumet Specialty Products Partners, L.P. and Calumet Finance Corp. completed an upsized private placement of US$405 million in 9.75% Senior Notes due 2031 under Rule 144A and Regulation S, issuing the notes at 98.996% of par for net proceeds of about US$393 million. The company plans to use the proceeds, alongside cash on hand and its revolving credit facility, to redeem its higher-coupon 11.00% 2026 and 8.125% 2027 senior notes, potentially...